MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

MannKind Corp

Fechado

SetorSaúde

5.21 -6.63

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.18

Máximo

5.38

Indicadores-chave

By Trading Economics

Rendimento

7.3M

8M

Vendas

5.6M

82M

P/E

Médio do Setor

50.7

90.831

Margem de lucro

9.722

Funcionários

403

EBITDA

8.1M

18M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+65.78% upside

Dividendos

By Dow Jones

Próximos Ganhos

25 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-125M

1.6B

Abertura anterior

11.84

Fecho anterior

5.21

Sentimento de Notícias

By Acuity

100%

0%

345 / 361 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de jan. de 2026, 23:29 UTC

Ações em Alta

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 de jan. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 de jan. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

16 de jan. de 2026, 21:48 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 de jan. de 2026, 21:41 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 de jan. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 de jan. de 2026, 20:44 UTC

Ganhos

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 de jan. de 2026, 20:42 UTC

Conversa de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 de jan. de 2026, 20:28 UTC

Conversa de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 de jan. de 2026, 19:12 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 de jan. de 2026, 18:53 UTC

Conversa de Mercado

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 de jan. de 2026, 18:41 UTC

Conversa de Mercado

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 de jan. de 2026, 18:31 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 de jan. de 2026, 16:32 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 de jan. de 2026, 16:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

65.78% parte superior

Previsão para 12 meses

Média 9.3 USD  65.78%

Máximo 11 USD

Mínimo 7.5 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

345 / 361 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat